UBS AM’s Tandem Diabetes Care TNDM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.29M | Sell |
151,847
-16,646
| -10% | -$291K | ﹤0.01% | 1986 |
|
|
2026
Q1 | $3.23M | Buy |
168,493
+3,591
| +2% | +$78K | ﹤0.01% | 1797 |
|
|
2025
Q4 | $3.62M | Sell |
164,902
-19,993
| -11% | -$361K | ﹤0.01% | 1619 |
|
|
2025
Q3 | $2.24M | Sell |
184,895
-84,008
| -31% | -$1.14M | ﹤0.01% | 1702 |
|
|
2025
Q2 | $5.01M | Buy |
268,903
+74,910
| +39% | +$1.48M | ﹤0.01% | 1702 |
|
|
2025
Q1 | $3.72M | Buy |
193,993
+16,254
| +9% | +$476K | ﹤0.01% | 1712 |
|
|
2024
Q4 | $6.4M | Buy |
177,739
+30,133
| +20% | +$1.02M | ﹤0.01% | 1478 |
|
|
2024
Q3 | $6.26M | Sell |
147,606
-5,546
| -4% | -$235K | ﹤0.01% | 1455 |
|
|
2024
Q2 | $6.17M | Buy |
153,152
+49,373
| +48% | +$2.06M | ﹤0.01% | 1382 |
|
|
2024
Q1 | $3.67M | Buy |
103,779
+11,309
| +12% | +$303K | ﹤0.01% | 1393 |
|
|
2023
Q4 | $2.74M | Sell |
92,470
-2,677
| -3% | -$55.5K | ﹤0.01% | 1532 |
|
|
2023
Q3 | $1.98M | Buy |
95,147
+3,194
| +3% | +$87.7K | ﹤0.01% | 1633 |
|
|
2023
Q2 | $3.73M | Hold |
91,953
| – | – | ﹤0.01% | 1364 |
|
|
2023
Q1 | $3.73M | Buy |
91,953
+3,585
| +4% | +$148K | ﹤0.01% | 1364 |
|
|
2022
Q4 | $3.97M | Buy |
88,368
+5,910
| +7% | +$268K | ﹤0.01% | 1245 |
|
|
2022
Q3 | $3.95M | Sell |
82,458
-11,675
| -12% | -$640K | ﹤0.01% | 1285 |
|
|
2022
Q2 | $5.57M | Sell |
94,133
-2,183
| -2% | -$179K | ﹤0.01% | 1175 |
|
|
2022
Q1 | $11.2M | Buy |
96,316
+6,418
| +7% | +$749K | ﹤0.01% | 1026 |
|
|
2021
Q4 | $13.5M | Sell |
89,898
-4,889
| -5% | -$660K | 0.01% | 1016 |
|
|
2021
Q3 | $11.3M | Buy |
94,787
+1,595
| +2% | +$176K | ﹤0.01% | 1045 |
|
|
2021
Q2 | $9.08M | Buy |
93,192
+7,510
| +9% | +$670K | ﹤0.01% | 1153 |
|
|
2021
Q1 | $7.56M | Sell |
85,682
-123,245
| -59% | -$11.5M | ﹤0.01% | 1178 |
|
|
2020
Q4 | $20M | Buy |
208,927
+5,704
| +3% | +$588K | 0.01% | 852 |
|
|
2020
Q3 | $23.1M | Buy |
203,223
+3,132
| +2% | +$329K | 0.01% | 730 |
|
|
2020
Q2 | $19.8M | Buy |
200,091
+14,196
| +8% | +$1.13M | 0.01% | 742 |
|
|
2020
Q1 | $12M | Sell |
185,895
-45,079
| -20% | -$3.16M | 0.01% | 816 |
|
|
2019
Q4 | $13.8M | Buy |
230,974
+175,380
| +315% | +$10.8M | 0.01% | 859 |
|
|
2019
Q3 | $3.28M | Buy |
55,594
+8,666
| +18% | +$553K | ﹤0.01% | 1387 |
|
|
2019
Q2 | $3.03M | Buy |
46,928
+5,768
| +14% | +$372K | ﹤0.01% | 1401 |
|
|
2019
Q1 | $2.61M | Buy |
41,160
+3,137
| +8% | +$165K | ﹤0.01% | 1394 |
|
|
2018
Q4 | $1.44M | Buy |
+38,023
| New | +$1.34M | ﹤0.01% | 1574 |
|
|
2014
Q3 | – | Sell |
-19,070
| Closed | -$3.1M | – | 2582 |
|
|
2014
Q2 | $3.1M | Sell |
19,070
-2,150
| -10% | -$366K | ﹤0.01% | 1172 |
|
|
2014
Q1 | $4.69M | Sell |
21,220
-3,580
| -14% | -$913K | 0.01% | 1051 |
|
|
2013
Q4 | $6.39M | Buy |
+24,800
| New | +$5.67M | 0.01% | 947 |
|
Other funds holding TNDM
SC
FLAM
GKIM
PIM
UBS AM's TNDM Position: Q2 2026 in Review
UBS AM reduced its Tandem Diabetes Care (TNDM) stake by 9.9% in Q2 2026, selling an estimated $291K and leaving 151,847 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1986.
UBS AM first reported a position in TNDM in Q4 2013 and has held it in 34 quarters since. The position peaked at $23.1M in Q3 2020. 273 funds tracked by Wall St. Rank hold TNDM as of Q2 2026.
- UBS AM held 151,847 shares of Tandem Diabetes Care worth $2.29M as of Q2 2026.
- UBS AM sold 16,646 Tandem Diabetes Care shares in Q2 2026, an estimated $291K.
- Tandem Diabetes Care made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1986 holding.
- UBS AM first reported a position in Tandem Diabetes Care in Q4 2013 and has held it in 34 quarters since.
- UBS AM's Tandem Diabetes Care position peaked at $23.1M in Q3 2020.
- 273 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.